Member Info for cj62

If not sacked at least driven through with a pitchfork.

That would liven the agm up a bit , fisticuffs in the stalls. Wish I was going now.

PL I would throw a few gum shields and bandages on you stall looks like they might be needed.

I would like to think that prior to the agm or in the update they will inform everyone the status of all cohorts. Efficacy hopefully will have been seen in the first 2w cohort , are they continuing on treatment? If fact a proper update

Don't be frightening the pussies now touk !!!

More worrying the bar isn't open until 3

No money left. We're doomed I tell ya we're doomed !!!

Gje306 ìf the SP hasn't improved significantly within the next 6 months we all been had.

And there lies the problem with you Thorn making statements without doing the slightest bit of research.

Twat

Near historical lows you say, do you even know what the historical low is ? No I suspected as much you clown.

He got caught nicking petri dishes

Largo any rise is very quickly sold into, I would love to know who it is as they seem to have an endless supply.

Maybe sooner but the votes will have been counted by then. 2w results will be out and hopefully it's good news then at least we won't have read their dross, even if it's bad I won't have to read their dross as I will leave gracefully and pick my financial wounds.

Me too , hopefully it's yhe bottom this time but as I have said before the only bottom I can find is the one I scratch in a morning

Baby reindeer springs to mind

In a nut shell !!! Recent updates on current lead asset AVA6000, a peptide-drug conjugate of doxorubicin, suggest the programme remains on track to move into dose expansion cohorts in H224. Most recently, AACR data confirm that AVA6000 is working as intended, with selective activation at the target tumour site, lower toxicities than standard doxorubicin, and anti-tumour effects in cancers with over-expression of FAP and that are sensitive to doxorubicin monotherapy. In addition, there have been no unexpected safety signals in the first dosing cohort of the optimised two-weekly schedule, important given the more frequent administration. Continued successful clinical progress with AVA6000 also helps to validate the proprietary pre|CISION platform. This could have wide ranging potential in oncology, with the opportunity to develop next-generation targeted cancer treatments. Details on the broader pre|CISION pipeline are expected in H224. Our valuation post FY23 results and the March fundraise is slightly increased to £675m (equivalent to 188p/share

BP Need to replace that amount of product due to lose exclusivity. Apologies if posted before

https://www.fiercebiotech.com/biotech/pharma-awaits-fed-relief-1t-firepower-spend-biotech-innovation-report

Or he's just a narcissist, luckily enough I have the boring twat filtered and he is the only one but thornogson is getting perilously close to the edge.

Weird world they live in.

VR still needs help typing a sentence, so it will be a few years before he progresses to posting links

There appears to be a persistent seller and my assumption is it's the same group. The question is who and why, the placing shares have churned through now so no profit only a loss to be made. Scalping I don't think so as the volume is low. Distressed seller neither so why ? 2w News is due within 6 weeks so why.

Intriguing to say the least

Well I think someone should email CC informing her of our present dilemma so ensuring the 26th June AGM isn't full of such ambiguous statements.

God forbid if there were , should we have a straw poll for which language should be used American or plain English in fact I demand she speaks with a English accent..

Lasso's and 6 shooters at the ready PL.

I should imagine we will all know the fate of avacta in say 4 months. 2w data should have been released by then. If its good we are off to the races.

Ice I love your optimistic view but it really isn't that clear cut.